Background: Since the efficacy of ranibizumab (RBZ), bevacizumab (BVZ) and aflibercept (AFB) is comparable in neovascular age-related macular degeneration (AMD), we conducted a systematic review and meta-analysis to evaluate the long-term safety profiles of these agents, including ocular safety. Methods: Systematic review identifying randomized controlled trials (RCTs) comparing RBZ, BVZ and AFB directly published before March 2019. Serious ocular adverse events (SOAE) of special interest were endophthalmitis, pseudo-endophthalmitis, retinal pigment epithelium tear and newly identified macular atrophy. Results: Thirteen RCTs selected for meta-analysis (4952 patients, 8723 people-years follow-up): 10 compared RBZ vs. BVZ and three RBZ vs. AFB. There were no significant differences in almost all adverse events (systemic and ocular) between BVZ, RBZ and AFB in up to two years’ follow-up. Macular atrophy was reported heterogeneously and not reported as SOAE in most trials. Conclusions: Direct comparison of RBZ, BVZ and AFB safety profiles in the RCT network meta-analytical setting have not revealed a consistent benefit of these three commonly used anti-vascular endothelial growth factor (anti-VEGF) agents in AMD. Network model ranking highlighted potential benefits of RBZ in terms of a systemic safety profile; however, this appears a hypothesis rather than a conclusion. Newly identified macular atrophy is underestimated in RCTs—future real-world data should be focused on SOAE.
Возрастная макулярная дегенерация (ВМД) — заболевание, развивающееся у лиц старшей возрастной группы, в основе патогенеза которого лежит поражение ретинального пигментного эпителия и мембраны Бруха. На сегодняшний день в мире известны восемь анти-VEGF-препаратов для лечения неоваскулярной формы ВМД (нВМД), четыре из них зарегистрированы и используются в клинической практике. Первым зарегистрированным препаратом был пегаптаниб, селективно блокирующий VEGF165. В дальнейшем появилась молекула с похожим механизмом действия: ранибизумаб представляет собой гуманизированный моноклональный Fab-фрагмент, специально разработанный для офтальмологии. Его преимущество перед пегаптанибом — в нейтрализации всех активных изоформ VEGF-A. Афлиберцепт и конберцепт — рекомбинантные гибридные белки, действующие как растворимые рецепторы-ловушки для белков семейства VEGF. Данные III фазы исследований VIEW 1 и 2 показали, что интравитреальное введение (ИВВ) афлиберцепта каждые 1 или 2 мес на протяжении года приводит к функциональным результатам, сопоставимым с таковыми после ежемесячных ИВВ ранибизумаба на протяжении года. В 2019 г. была зарегистрирована следующая молекула для анти-VEGF-терапии, показавшая эффективность, — бролуцизумаб (одноцепочечный фрагмент гуманизированного антитела). Бролуцизумаб с высокой аффинностью связывается с различными изоформами VEGF-A. Параллельно с исследованием бролуцизумаба проводилось изучение Abicipar pegol, но данный препарат не был зарегестрирован из-за высокого процента осложнений. Последним из зарегистрированных препаратов для лечения нВМД стал фарицимаб. Молекула этого препарата представляет собой гуманизированное антитело иммуноглобулина G, воздействующее на две ключевые точки ангиогенеза: VEGF-A и ангиопоэтин-2 (Ang-2). Таким образом, стратегия развития анти-VEGF-терапии заключается в создании молекул с большей эффективностью (с лучшим воздействием на новообразованные сосуды, приводящим к резорбции экссудата в сетчатке, под нейроэпителием и под ретинальным пигментным эпителием), что позволяет не только сохранить зрение, но и при отсутствии макулярной атрофии существенно его повысить.
A data analysis on the actual direction of biomedicine, the study of biomarkers in diabetic retinopathy (DR), was done. Biomarkers identification is important for screening, diagnosis, monitoring, prevention and prediction of the clinical response of the patient to the treatment. In addition, studying the biomarkers allows increase of the effectiveness and safety of using various treatment options. The review examines two main groups of biomarkers, molecular and visualised, which shows the current state of the problem and the prospects for studying biomarkers in the context of the DR treatment. Nowadays, searching for and finding new biomarkers is important and will allow us to develop individual treatment regimens for DR and personalised medicine in an interdisciplinary aspect: ophthalmology and endocrinology.
1 July 2021 in Pattern Recognition and Image Analysis
This article presents the results of the joint work of image analysis specialists and ophthalmologists on the problem of analyzing images obtained by optical coherence tomography (angiography). A descriptive algorithmic scheme for analyzing images obtained using optical coherence tomography angiography was constructed to automate detection of pathological changes in the morphometric characteristics of the fundus. The algorithmic scheme is based on the image processing, analysis, and recognition methods. A feature space has been developed that makes it possible to identify pathological changes in the structure of the vascular plexuses of the human retina. It was possible to achieve high-accuracy classification of images of healthy eyes and those with pathology. Analysis of correlation between the features and investigated structural, clinical, and functional parameters can be used to confirm that the selected features are informative diagnostic and prognostic markers, and automated analysis using the proposed algorithm makes it possible to speed up and optimize the procedure for interpreting images of this class. Software has been created that allows, with high accuracy in an autonomous mode, performing differential diagnostics of the normal state of vessels from the pathological one, which increases its diagnostic value. In the future, more detailed work is planned with “borderline” conditions, which constitute the main problem in screening patients with diabetes mellitus.
Background. Coagulase-negative staphylococci (CNS), primarily Staphylococcus epidermidis, predominate in the normal microflora of the eye. However, due to irrational antibiotic therapy, resistant strains are widely distributed among CNS. Objective. To study the sensitivity of the antibiotic resistant CNS isolates to the antiseptic picloxydine dihydrochloride ("Vitabact"). Methods. Species, sensitivity to antibiotics and antiseptic picloxydine dihydrochloride were determined for 39 isolates of bacteria obtained from the conjunctival swabs. The cells morphology under the influence of antiseptic was studied by electron microscopy. Results. 33 isolates of S. epidermidis (17 sensitive or resistant to drugs of no more than 2 classes of antibiotics and 16 MDR), 2 S. haemolyticus (1 resistant to 2 classes of antibiotics and 1 MDR), 3 S. hominis (1 sensitive and 2 MDR), 1 S. caprae (MDR) were characterized. In vitro tests, the antiseptic picloxydine dihydrochloride showed high efficiency in suppressing the growth of staphylococci regardless of their sensitivity to antibiotics, as well as bactericidal activity at concentration of 31.2 g/ml. In this concentration, the antiseptic had a pronounced destructive effect on the surface structures of bacterial cells. Conclusion. Antiseptic picloxydine dihydrochloride is effective against antibiotic resistant coagulase-negative staphylococci.
The widespread introduction of intravitreal drug injections into clinical practice has highlighted a number of issues to be solved, including the risk of serious complications, the treatment burden on patients and the patient’s insufficient adherence to treatment, as well as a significant effect on the healthcare cost and effort. One of the ways to resolve the issues is to increase the patients’ awareness concerning the therapy they are about to receive, which contributes to the patients’ understanding of the details of treatment and enables them to make correct decisions. The best option of presenting such information to the patient is to provide them with a written document. The Expert Council on Retinal and Optic Nerve Diseases of the All-Russian Association of Ophthalmologists has developed, approved and tested an information brochure for patients who receive intravitreal injections. It offers brief information on what the procedure is, contraindications, details of preparation, and symptoms, both common ones and those requiring emergency assistance. The paper outlines the results of the study and presents a layout of an information leaflet for patients recommended for use in the Russian Federation.